RIGHT Checklist

RIGHT (Reporting Items for practice Guidelines in HealThcare) Checklist

22 Sections/topics and 35 Items Assessment Page(s) Note(s)

Section/topic No./ Item

Basic information

Title/subtitle

Yes 1
Identify the report as a guideline, that is, with No
1a
“guideline(s)” or “recommendation(s)” in the title. Unclear

Yes 1
No
1b Describe the year of publication of the guideline.
Unclear

Yes 1
Describe the focus of the guideline, such as No
1c screening, diagnosis, treatment, management,
Unclear
prevention, or others.

Executive summary

Yes 2
Provide a summary of the recommendations No
2
contained in the guideline. Unclear

Abbreviations and acronyms

Yes 2-3
Define new or key terms, and provide a list of No
3
abbreviations and acronyms if applicable. Unclear

Corresponding developer

Yes 1
Identify at least 1 corresponding developer or author No
4
who can be contacted about the guideline. Unclear

Background

Brief description of the health problem(s)

Yes 4-5
Describe the basic epidemiology of the problem, No
such as the prevalence/incidence, morbidity,
5
mortality, and burden (including financial) resulting
Unclear
from the problem.

Aim(s) of the guideline and specific objectives

 Yes 4-5
Describe the aim(s) of the guideline and specific No
objectives, such as improvements in health Unclear
6
indicators (e.g., mortality and disease prevalence),
quality of life, or cost savings.

Target populations

Yes 5
Describe the primary population(s) that is affected No
7a
by the recommendation(s) in the guideline.
Unclear

Yes 5
Describe any subgroups that are given special No
7b
consideration in the guideline.
Unclear

End users and settings

Yes 5
Describe the intended primary users of the guideline No
(such as primary care providers, clinical specialists,
8a public health practitioners, program managers, and Unclear
policymakers) and other potential users of the
guideline.

Yes 5
Describe the setting(s) for which the guideline is No
8b intended, such as primary care, low- and
middleincome countries, or inpatient facilities.
Unclear

Guideline development groups

Yes N/A described in

Describe how all contributors to the guideline No
the JSHA
development were selected and their roles and
9a responsibilities (e.g., steering group, guideline panel, author
Unclear
external reviewer, systematic review team, and contribution
methodologists). form

Yes 1 and
List all individuals involved in developing the No
9b guideline, including their title, role(s) and 19
institutional affiliation(s).
Unclear

Evidence

Health care questions

10a State the key questions that were the basis for the Yes
recommendations in PICO (population, intervention, No
comparator, and outcome) or other format as Unclear
appropriate.

Yes 5
No
Indicate how the outcomes were selected and
10b Unclear
sorted.
Systematic reviews

Yes 5
Indicate whether the guideline is based on new No
11a systematic reviews done specifically for this guideline
Unclear
or whether existing systematic reviews were used.

Yes
If the guideline developers used existing systematic No
reviews, reference these and describe how those Unclear
reviews were identified and assessed (provide the
11b
search strategies and the selection criteria, and
describe how the risk of bias was evaluated) and
whether they were updated.

Assessment of the certainty of the body of evidence

Yes 5 + Table
Describe the approach used to assess the certainty of No
1
12
the body of evidence. Unclear

Recommendations

Recommendations

Yes 21-41
Provide clear, precise, and actionable No
13a
recommendations. Unclear

Yes 21-41
Present separate recommendations for important No
subgroups if the evidence suggests that there are Unclear
13b important differences in factors influencing
recommendations, particularly the balance of benefits
and harms across subgroups.

Yes 21-41
Indicate the strength of recommendations and the No
13c
certainty of the supporting evidence. Unclear

Rationale/explanation for recommendations

Yes 5-17
Describe whether values and preferences of the No
target population(s) were considered in the Unclear
formulation of each recommendation. If yes,
14a describe the approaches and methods used to elicit
or identify these values and preferences. If values
and preferences were not considered, provide an
explanation.

14b Describe whether cost and resource implications were Yes local
considered in the formulation of recommendations. If No
studies
yes, describe the specific approaches and methods Unclear
used (such as cost-effectiveness analysis) and not
summarize the results. If resource issues were not available
considered, provide an explanation.
 Yes 5-17
Describe other factors taken into consideration when No
14c formulating the recommendations, such as equity, Unclear
feasibility and acceptability.
Evidence to decision processes

Yes 5
Describe the processes and approaches used by the No
guideline development group to make decisions, Unclear
15 particularly the formulation of recommendations
(such as how consensus was defined and achieved
and whether voting was used).

Review and quality assurance

External review

Yes peer
No
review
Indicate whether the draft guideline underwent Unclear
after
16 independent review and, if so, how this was executed
and the comments considered and addressed. submission
6
reviewers

Quality assurance

Yes
Indicate whether the guideline was subjected to a No
17 quality assurance process. If yes, describe the Unclear
process.

Funding, declaration and management of interests

Funding source(s) and role(s) of the funder

Yes 19
No
Describe the specific sources of funding for all
18a Unclear
stages of guideline development.

Yes 19
Describe the role of funder(s) in the different stages No
18b of guideline development and in the dissemination Unclear
and implementation of the recommendations.

Declaration and management of interest

Yes 19
No
Describe what types of conflicts (financial and
19a Unclear
nonfinancial) were relevant to guideline development.

Yes no
Describe how conflicts of interest were evaluated and No
conflicts
19b managed and how users of the guideline can access Unclear
the declarations.

Other information

Access

Yes to be
No
Describe where the guideline, its appendices, and published
20 Unclear
other related documents can be accessed. in JSHA
Suggestions for further research

Yes
No
Describe the gaps in the evidence and/or provide
21 Unclear
suggestions for future research.

Limitations of the guideline

Yes

Describe any limitations in the guideline development No

process (such as the development groups were not Unclear
multidisciplinary or patients’ values and preferences
22
were not sought), and indicate how these limitations
might have affected the validity of the
recommendations.

Reference:
Chen Y, Yang K, Marušić A, et al. A Reporting Tool for Practice Guidelines in Health Care: The RIGHT Statement[J].
Annals of Internal Medicine, 2017, 166(2):128-132. https://doi.org/10.7326/M16-1565
Official Website: http://www.right-statement.org/